Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$62.21
-1.8%		$64.09
$49.26
▼
$70.98
$12.27B0.241.85 million shs2.11 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$16.23
-5.3%		$23.58
$11.92
▼
$27.31
$3.20B1.083.30 million shs2.64 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$112.44
-2.3%		$98.92
$61.22
▼
$116.85
$13.07B0.882.01 million shs2.70 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$513.02
-1.1%		$528.14
$393.61
▼
$615.00
$11.99B-0.98210,227 shs315,949 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-1.83%-3.89%-4.40%+8.47%+16.48%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-5.31%-6.24%-37.55%-21.25%+23.05%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.34%+3.69%+3.50%+54.79%+44.95%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-1.12%-3.04%+0.21%-0.15%+15.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$62.21
-1.8%		$64.09
$49.26
▼
$70.98
$12.27B0.241.85 million shs2.11 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$16.23
-5.3%		$23.58
$11.92
▼
$27.31
$3.20B1.083.30 million shs2.64 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$112.44
-2.3%		$98.92
$61.22
▼
$116.85
$13.07B0.882.01 million shs2.70 million shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$513.02
-1.1%		$528.14
$393.61
▼
$615.00
$11.99B-0.98210,227 shs315,949 shs
10 Best Stocks to Own - Fall 2026 Cover
10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-1.83%-3.89%-4.40%+8.47%+16.48%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-5.31%-6.24%-37.55%-21.25%+23.05%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.34%+3.69%+3.50%+54.79%+44.95%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-1.12%-3.04%+0.21%-0.15%+15.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.70
Moderate Buy$89.1743.34% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.81
Moderate Buy$32.1798.19% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.62
Moderate Buy$91.20-18.89% Downside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$701.3336.71% Upside

Current Analyst Ratings Breakdown

Latest DYN, HALO, BMRN, and MDGL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/23/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform ➝ Buy$725.00
9/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
9/16/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/10/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$60.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$45.00 ➝ $36.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$30.00 ➝ $26.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$35.00 ➝ $30.00
9/9/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Underweight$17.00 ➝ $10.00
9/8/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$37.00
9/3/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
9/2/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$115.00
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.41B3.53$2.80 per share22.21$31.68 per share1.96
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.81 per shareN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B9.14$4.66 per share24.13$0.42 per share267.71
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.37N/AN/A$26.54 per share19.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37168.1411.480.452.14%5.32%3.69%10/26/2026 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.3533.5612.050.4424.86%260.98%23.91%11/2/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A92.44N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)

Latest DYN, HALO, BMRN, and MDGL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/6/2026Q2 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.79$2.28+$0.49$1.90$402.28 million$481.00 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
2.71
2.31
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94

Institutional Ownership

CompanyInstitutional Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%

Insider Ownership

CompanyInsider Ownership
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
258186.75 million169.08 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423113.50 million110.66 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable

Recent News About These Companies

Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target
September 23 at 9:47 AM  |  marketscreener.comM
Madrigal Pharmaceuticals stock falls 1.80 percent as valuation stays high
September 22 at 12:50 PM  |  ad-hoc-news.deA
Madrigal Pharmaceuticals stock trades around 531 dollars as institutional interest stays strong
September 21 at 10:00 AM  |  ad-hoc-news.deA
Madrigal Pharmaceuticals stock holds above 530 dollars after recent ownership change
September 20, 2026  |  ad-hoc-news.deA
Bank of America Corp DE Purchases Shares of 134,036 Madrigal Pharmaceuticals, Inc. $MDGL
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-shares-of-134036-madrigal-pharmaceuticals-inc-mdgl-2026-09-20/
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - September 16, 2026
September 17, 2026  |  biospace.comB
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363532/0/en/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells 5,221 Shares of Stock
September 12, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mdgl-insider-buying-and-selling-2026-09-12/
Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 5,221 Shares
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-madrigal-pharmaceuticals-nasdaq-mdgl-ceo-william-john-sibold-sells-5221-shares-2026-09-11/
William John Sibold Sells 6,362 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-william-john-sibold-sells-6362-shares-of-madrigal-pharmaceuticals-nasdaq-mdgl-stock-2026-09-11/
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
September 10, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945194-madrigal-pharmaceuticals-inc-mdgl-presents-at-12th-annual-cantor-fitzgerald-global-healthcare
Hsbc Holdings PLC Grows Stake in Madrigal Pharmaceuticals, Inc. $MDGL
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-grows-stake-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-10/
Madrigal Pharmaceuticals, Inc. $MDGL Shares Purchased by California State Teachers Retirement System
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-has-496-billion-stock-position-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-10/
Public Employees Retirement System of Ohio Invests $2.74 Million in Madrigal Pharmaceuticals, Inc. $MDGL
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-invests-274-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-06/
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-increases-stock-holdings-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-05/
Legal & General Group Plc Invests $6.63 Million in Madrigal Pharmaceuticals, Inc. $MDGL
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-663-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-03/
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
September 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference-1036515145
Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355104/0/en/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-conference.html
Two Sigma Securities LLC Makes New Investment in Madrigal Pharmaceuticals, Inc. $MDGL
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-two-sigma-securities-llc-makes-new-investment-in-madrigal-pharmaceuticals-inc-mdgl-2026-09-01/
The Manufacturers Life Insurance Company Invests $6.55 Million in Madrigal Pharmaceuticals, Inc. $MDGL
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-invests-655-million-in-madrigal-pharmaceuticals-inc-mdgl-2026-08-31/
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Rating of "Moderate Buy" by Analysts
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-madrigal-pharmaceuticals-inc-nasdaq-mdgl-given-consensus-rating-of-moderate-buy-by-analysts-2026-08-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Desk with a monitor showing an upward stock price chart, printed financial reports, and a bronze bull statue.
3 Earnings Season Winners That Analysts Can't Stop Upgrading
By Dan Schmidt | September 7, 2026
Digital illustration of glowing servers, cloud icons, and data charts connected by light streams, symbolizing cloud computing and data networks.
3 Software Stocks Rebounding as AI Fears Give Way to Growth
By Leo Miller | September 21, 2026
Worker in a safety vest and hard hat inspects steel beams inside a metal fabrication warehouse near rail cars.
Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong
By Chris Markoch | September 22, 2026
BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$62.21 -1.16 (-1.83%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$62.20 -0.02 (-0.02%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$16.23 -0.91 (-5.31%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$16.22 -0.01 (-0.09%)
As of 05:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$112.44 -2.69 (-2.34%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$112.67 +0.23 (+0.20%)
As of 05:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$513.02 -5.81 (-1.12%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$516.81 +3.79 (+0.74%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas